Understanding LDN 1.
LDN 1.5 mg is a low-dose naltrexone formulation manufactured by Healing Pharma, specifically developed for laboratory research investigating opioid receptor antagonism at sub-therapeutic concentrations. This compound represents a µ-opioid receptor antagonist that demonstrates unique pharmacological properties when studied at doses significantly below traditional clinical applications. Research scientists at Stroid UK Shop utilize this formulation to examine the complex interactions between opioid receptor modulation and various physiological pathways in controlled laboratory environments.
Scientific Applications
Laboratory studies examine LDN’s capacity to modulate endorphin production through temporary opioid receptor blockade mechanisms. Research protocols investigate how brief receptor antagonism may influence endogenous opioid system function in cellular and tissue models. Scientists study the compound’s effects on immune system modulation, particularly focusing on glial cell activation and cytokine expression patterns. The precise 1.5 mg dosing allows researchers to investigate threshold effects and dose-response relationships in various experimental paradigms. Investigations encompass autoimmune research models, inflammatory response studies, and neuroinflammation research protocols. Researchers exploring miscellaneous research compounds often incorporate LDN studies alongside other receptor modulators. The compound’s research applications extend to studies examining circadian rhythm effects and sleep-wake cycle modulation. Scientists also investigate potential interactions with other research compounds commonly found in SARMs and peptide research protocols.
Technical Specifications
| Parameter | Specification |
|---|---|
| Compound Name | Naltrexone Hydrochloride (Low Dose) |
| Strength | 1.5 mg per capsule |
| Manufacturer | Healing Pharma |
| Form | Oral capsules |
| CAS Number | 16676-29-2 (naltrexone HCl) |
| Molecular Formula | C20H23NO4·HCl |
| Molecular Weight | 377.86 g/mol |
| Storage Conditions | Room temperature, dry environment |
Research Compliance
This product is manufactured exclusively for in-vitro laboratory research and analytical testing purposes. LDN 1.5 mg is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must maintain appropriate documentation, storage protocols, and handling procedures in accordance with institutional research guidelines. All studies should be conducted under proper laboratory supervision with appropriate safety measures and regulatory compliance.
